Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (BRKR) delivers innovative analytical instrumentation and diagnostic solutions for life sciences, pharmaceuticals, and industrial applications. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and technological advancements.
Access comprehensive coverage of Bruker's press releases, including earnings reports, product launches, strategic partnerships, and regulatory milestones. Our curated news collection simplifies tracking market-moving events and understanding their impact on Bruker's position in scientific instrumentation markets.
Key content categories feature updates across Bruker's business segments - from BSI BioSpin's research tools to BEST's energy innovations. Stay informed about operational expansions, R&D breakthroughs, and quality assurance initiatives that drive the company's global success.
Bookmark this page for direct access to verified Bruker announcements and analysis. Monitor evolving trends in analytical technology through reliable updates from one of the industry's most established instrumentation providers.
Bruker (Nasdaq: BRKR) has unveiled the OptoVolt™ module at the Neuroscience 2024 conference, enhancing their Ultima multiphoton microscope platform for advanced neuroscience research. This innovative solution enables imaging speeds beyond 1000 frames per second, allowing researchers to capture millisecond dynamics of neural communication at single neuron resolution.
The OptoVolt module addresses challenges in voltage imaging with its ultrafast scanner technology and high signal-to-noise ratio. When combined with Bruker's NeuraLight 3D Ultra® spatial light modulator, it enables researchers to probe input-output relationships of neural ensembles at unprecedented temporal and spatial resolutions.
Professor Thomas Clandinin from Stanford University expressed excitement about the potential of voltage imaging in neural circuit investigation and systems neuroscience. Xiaomei Li, Ph.D., Vice President at Bruker, emphasized the company's commitment to addressing evolving research needs through customer collaboration.
Bruker (Nasdaq: BRKR) has acquired Dynamic Biosensors GmbH, a Munich-based pioneer in biosensor development. This acquisition enhances Bruker's biophysical portfolio for analyzing molecular interactions and kinetics in drug discovery and basic research. Dynamic Biosensors' innovative technologies include:
1. The heliXcyto instrument for single-cell Interaction Cytometry (scIC)
2. The heliX+ instrument using switchSENSE® technology with DNA nanolevers
These complement Bruker's Surface Plasmon Resonance (SPR) portfolio, including the new SPR #64 'Triceratops' and Sierra-Pro SPR systems. The combined Bruker Biosensors business now offers a comprehensive range of instruments, workflows, and consumables for studying inter-molecular and molecule-cell interactions in drug discovery. Financial details were not disclosed, but Bruker expects additional revenues greater than $5 million from the acquisition in FY2025, with no material EPS impact.
Bruker (Nasdaq: BRKR) has announced its participation in two upcoming investor conferences. Gerald Herman, Executive Vice President & CFO, will represent the company at both events:
1. The 2024 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time.
2. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024, at 10:00 a.m. Eastern Time.
Live audiovisual webcasts of the presentations will be available on the company's Investor Relations website. Replays will be accessible for 90 days after the events in the 'Events & Presentations' section.
Bruker has successfully installed Asia's first 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute (KBSI). This ultra-high field NMR system sets a new benchmark for molecular, cell biology, and disease research in the Asia-Pacific region. The installation enhances KBSI's capabilities in biomolecular structure analysis and drug development, enabling researchers to observe functional molecular dynamics and structural rearrangements in real time.
The 1.2 GHz NMR spectrometer will support various research applications, including the study of intrinsically disordered proteins, drug-target binding mechanisms, and the development of diagnostic methods for infectious diseases. With this installation, there are now 22 GHz-class NMR spectrometers worldwide, highlighting the growing importance of advanced NMR technology in scientific research.
Bruker (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.05 per share on its common stock. The dividend is set to be paid on September 16, 2024, to stockholders of record as of September 2, 2024. This decision, approved by Bruker's Board of Directors, demonstrates the company's commitment to returning value to its shareholders through regular dividend payments.
Bruker (Nasdaq: BRKR) has announced a strategic minority investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in drug discovery services. The investment aims to accelerate NovAliX's growth and expansion in Europe and the United States. The partnership will focus on developing novel drug discovery technologies and methods, leveraging biophysical methods, particularly NMR.
Key collaboration areas include:
- Ultra-high field NMR for structural and binding investigations
- NMR-powered medicinal chemistry and mechanism of action research
- X-ray crystallography for structure-guided drug discovery
- High-sensitivity SPR for kinetics and binding studies
- Mass spectrometry for proteomics and multiomics
- Single cell and spatial biology tools for drug discovery insights
The partnership aims to enable new paradigms in drug discovery, accelerate development of advanced biophysical methods, and support the discovery of new and better medicines.
Bruker (Nasdaq: BRKR) reported strong Q2 2024 financial results with revenues of $800.7 million, up 17.4% year-over-year. Organic revenue grew 7.4%, while constant-exchange rate (CER) revenue increased 18.5%. The company's Q2 2024 GAAP EPS was $0.05, and non-GAAP EPS reached $0.52, up 4.0% year-over-year.
Bruker has increased its FY 2024 revenue guidance to $3.38-$3.44 billion, implying 14-16% growth. The company completed three strategic acquisitions in H1 2024, accelerating its portfolio transformation. Despite recent acquisitions impacting margins, Bruker expects steady margin expansion and rapid EPS growth in the next three years.
Bruker (Nasdaq: BRKR) has announced the date and time for its second quarter 2024 earnings release and webcast. The company will report financial results on Tuesday, August 6, 2024, before the market opens. A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results and current business trends.
Investors can access the webcast at https://ir.bruker.com under the 'Events & Presentations' section. A slide presentation will be available shortly before the webcast begins. For those preferring to listen via telephone, the dial-in numbers are 1-888-437-2685 (U.S. toll-free) or +1-412-317-6702 (international).
Bruker is offering a pre-registration option for the earnings call at https://dpregister.com/sreg/10191132/fd22c94e58. A replay will be available until September 6, 2024, by dialing 1-877-344-7529 (U.S. toll-free) or +1-412-317-0088 (international) with the access code: 2885668.
Bruker (Nasdaq: BRKR) announced the suspension of an injunction affecting sales of CosMx™ Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This development is related to ongoing patent litigation with 10x Genomics. The suspension was made possible after Bruker posted a bond authorized by the Munich Higher Regional Court.
The German Higher Regional Court of Munich had previously granted NanoString the right to lift the injunction, citing concerns with the lower Munich Regional Court's May 2023 decision. The Court noted that the lower court had failed to address relevant aspects of the case, including a disputed feature of the patent at issue.
As a result, all CosMx products are now available again to German scientific instrument customers, effective immediately.
Bruker (Nasdaq: BRKR) has successfully installed a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in Q2 2024. This advanced system will significantly enhance research capabilities in structural biology, pharmacology, and cellular biology by providing detailed insights into biomolecular structures and functions. The 1.2 GHz NMR system is expected to enable significant advancements in the understanding of intrinsically disordered proteins, which play critical roles in diseases like cancer and infectious diseases. It will support the characterization of novel active compounds and mechanisms of action, aiding in drug development efforts. FMP is already equipped with eleven NMR systems, and this latest addition marks a substantial evolution in its research capabilities. Key figures at FMP, including Dr. Peter Schmieder and Professors Hartmut Oschkinat and Adam Lange, emphasize the transformative potential of this technology in their research endeavors. Bruker expresses its commitment to supporting groundbreaking discoveries at FMP.
